Drug Trial Radar · NCT06477926
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jul 9, 2024
Primary completion
Sep 20, 2024
Study completion Sep 20, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the pharmacokinetics of the ER tablets under fasting and fed conditions in healthy adults.
Conditions
- Healthy Volunteers
Interventions
ABBV-668 IRDrug
• Oral Capsule
ABBV-668 ERDrug
• Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ABBV-668Time frame: Up to approximately 47 days
- Time to Cmax (Tmax) of ABBV-668Time frame: Up to approximately 47 days
- Terminal Phase Elimination Rate Constant (Beta) of ABBV-668Time frame: Up to approximately 47 days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-668Time frame: Up to approximately 47 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-668Time frame: Up to approximately 47 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-688Time frame: Up to approximately 47 days
- Number of Participants With Adverse Events (AEs)Time frame: Up to Day 47
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 266960
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.